Toshali Pandey

Resident physician

University of Arkansas for Medical Sciences

faculty

2 h-index 17 pubs 7 cited

Research Areas

Quality of Life Esophageal Stricture Research Gastroenterology Training Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immune Response and Inflammation SARS-CoV-2 and COVID-19 Research Meta-analysis and systematic reviews

Links

ORCID Lab Website

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Toshali Pandey's research has focused on evaluating quality of life and treatment outcomes for patients with esophageal strictures, particularly those induced by corrosive agents. Her work includes assessing the validity and reliability of specific quality of life questionnaires in this patient population and examining the impact of long-term endoscopic dilation on their nutritional status and quality of life. Pandey has also investigated the effects of the COVID-19 pandemic on gastroenterology training in India. Additionally, her research extends to hematologic oncology, with publications on peripheral blood immune cell profiling in response to CAR-T cell therapy for multiple myeloma, predicting survival based on drug-induced rash after mogamulizumab administration in mycosis fungoides/sezary syndrome, and identifying risk factors for acute kidney injury in patients receiving CAR-T cells. She has also explored the role of cytokine release syndrome as a trigger for detecting cancer therapy-related cardiac dysfunction after CAR-T therapy.

Metrics

h-index: 2
Publications: 17
Citations: 7

Selected Publications

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026) DOI
Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis (2025) DOI
AKI in Patients Receiving Chimeric Antigen Receptor T Cells: Risk Factors and Characteristics (2025) DOI
Revaccination status after bone marrow transplant and chimeric antigen receptor T-cell therapy. (2025) DOI
MRI lesion burden as a predictor of progression and survival in smoldering multiple myeloma. (2025) DOI
Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review. (2025) DOI
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience (2025) DOI
A Case Report on Pulmonary Tumor Embolism in a Patient With a Metastatic Gastrointestinal Stromal Tumor Invading the Inferior Vena Cava: Tumor or Thrombus? (2025) DOI
Simultaneous Presentation of Relapsed Diffuse Large B-cell Lymphoma and Extrapulmonary Tuberculosis in a Patient With HIV: A Case Report (2025) DOI
Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience (2024) DOI